View Financial HealthHantech Bio-Technology 배당 및 자사주 매입배당 기준 점검 3/6Hantech Bio-Technology 수익으로 충분히 충당되는 현재 수익률 4.28% 보유한 배당금 지급 회사입니다. 다음 지급일은 31st July, 2026 이며 배당락일은 다음과 같습니다. 3rd July, 2026.핵심 정보4.3%배당 수익률0.6%자사주 매입 수익률총 주주 수익률4.9%미래 배당 수익률n/a배당 성장률60.0%다음 배당 지급일31 Jul 26배당락일03 Jul 26주당 배당금n/a배당 성향61%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.공시 • Mar 04Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county TaiwanBoard Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 16Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m).Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).Reported Earnings • May 16First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024)First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue.New Risk • Apr 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m).Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year.Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023)Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.공시 • Mar 08Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county TaiwanNew Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m).New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m).Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year.Buy Or Sell Opportunity • Oct 11Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year.New Risk • Sep 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m).New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding).New Risk • Jul 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m).New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change).New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m).New Risk • Jul 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, 1294 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: 1294 의 배당금 지급이 증가했지만 회사는 3 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Hantech Bio-Technology 배당 수익률 vs 시장1294의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1294)4.3%시장 하위 25% (TW)1.4%시장 상위 25% (TW)4.9%업계 평균 (Personal Products)5.7%분석가 예측 (1294) (최대 3년)n/a주목할만한 배당금: 1294 의 배당금( 4.28% )은 TW 시장에서 배당금 지급자의 하위 25%( 1.43% )보다 높습니다.고배당: 1294 의 배당금( 4.28% )은 TW 시장에서 배당금 지급자의 상위 25%( 4.94% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 60.6% )을 통해 1294 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: 합리적인 현금 지급 비율 ( 60.5% )로 1294 의 배당금 지급은 현금 흐름으로 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YTW 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/08 02:57종가2026/07/08 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hantech Bio-Technology Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hsiu Chi LinMasterlink Securities Investment AdvisoryKyeongkeun KangNH Investment & Securities Co., Ltd.
Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).
Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.
Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).
Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.
공시 • Mar 04Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county Taiwan
Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 16Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.
New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m).
Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).
Reported Earnings • May 16First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024)First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue.
New Risk • Apr 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m).
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year.
Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023)Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.
공시 • Mar 08Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county Taiwan
New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m).
New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m).
Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year.
Buy Or Sell Opportunity • Oct 11Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year.
New Risk • Sep 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m).
New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding).
New Risk • Jul 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m).
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change).
New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m).
New Risk • Jul 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).